Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126579071 | 12657907 | 1 | I | 20160809 | 20160817 | 20160817 | EXP | JP-ROCHE-1814352 | ROCHE | KAMEI K. REVIEW OF SERUM IGG LEVELS AND INFECTION DURING B CELL DEPLETION BY RITUXIMAB THERAPY IN REFRACTORY NEPHROTIC SYNDROME. THE 51ST ANNUAL MEETING OF THE JAPANESE SOCIETY FOR PEDIATRIC NEPHROLOGY 2016 JUL;:125-. | 10.00 | YR | F | Y | 0.00000 | 20160817 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126579071 | 12657907 | 1 | PS | Rituximab | RITUXIMAB | 1 | Unknown | U | 103705 | ||||||||||
| 126579071 | 12657907 | 2 | SS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | Unknown | U | 50722 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126579071 | 12657907 | 1 | Nephrotic syndrome |
| 126579071 | 12657907 | 2 | Nephrotic syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126579071 | 12657907 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126579071 | 12657907 | Agranulocytosis | |
| 126579071 | 12657907 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |